Psychiatry & Neurology Doctors in Framingham, MA Accepting Medicare

27 Psychiatry & Neurology doctors found. Showing 21 - 27

Martin A Bielawski, M.D. Psychiatry & Neurology - Neurology Medicare: Medicare Enrolled Practice Location: 463 Worcester Rd, Suite 101, Framingham, MA 01701 Phone: 508-879-0888    Fax: 508-626-1985

William Wiener, M.D. Psychiatry & Neurology - Neurology Medicare: Not Enrolled in Medicare Practice Location: 463 Worcester Rd, Suite 101, Framingham, MA 01701 Phone: 508-879-0014    Fax: 508-626-1985

Virginia Merritt, M.D. Psychiatry & Neurology - Child & Adolescent Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 63 Fountain St Ste 402, Framingham, MA 01702 Phone: 508-872-4813

Maitri R Patel, MD Psychiatry & Neurology - Child & Adolescent Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 1881 Worcester Rd Ste 203, Framingham, MA 01701 Phone: 508-834-3183    Fax: 508-532-1168

Dr. Nicole V. Christian-brathwaite, MD Psychiatry & Neurology - Psychiatry Medicare: Medicare Enrolled Practice Location: 1 Frederick Abbott Way, Framingham, MA 01701 Phone: 508-879-9800    Fax: 508-875-1348

Dr. Christopher David Gordon, MD Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 1881 Worcester Road, Framingham, MA 01701 Phone: 508-628-6652    Fax: 508-861-0933

Philip R Sullivan, M.D. Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 393 Worcester Rd, 2nd Floor, Framingham, MA 01701 Phone: 508-875-0099

News Archive

Shield commences two ST10 Phase 3 studies in iron deficiency anaemia

Shield Therapeutics (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need, today announced that the first patients have been treated in the two Phase 3 clinical studies of ST10 for the treatment of iron deficiency anaemia (IDA) in subjects with inflammatory bowel disease.

Researchers find link between generalized anxiety disorder at age 18 and later alcohol use

Researchers at the University of Bristol have found evidence of an association between generalized anxiety disorder at age 18 and harmful drinking three years later, thanks to the long-term health study Children of the 90s.

CytRx updates on progress in clinical development of bafetinib in three oncology indications

CytRx Corporation, a biopharmaceutical company specializing in oncology, announces progress with its clinical program to evaluate the preliminary efficacy and safety of its drug candidate bafetinib in three oncology indications. The Company has enrolled its first patient in a Phase 2 proof-of-concept trial in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL), is reporting rapid advancement toward the initiation of a Phase 2 proof-of-concept trial in advanced prostate cancer, and is on track to begin clinical evaluation later this year in glioblastoma multiforme, a common and aggressive type of primary brain tumor.

Chief medical officer offers tips to women for better heart health

With Valentine's Day on the horizon, most people's thoughts turn to matters of the heart. Although it's great fun to play Cupid this time of year, February is also American Heart Month — an important time for women in particular to understand their health risks.

Phase II clinical trial results of Liposome-Entrapped Paclitaxel announced

NeoPharm, Inc. today announced the results of a Phase II clinical trial of Liposome-Entrapped Paclitaxel (LEP) an active component of Taxol®. This multicenter, open-label trial of LEP was conducted at 5 centers in India.

Read more Medical News

› Verified 3 days ago

• 1
• 2(current)